Logo-jrip
Submitted: 23 Feb 2024
Accepted: 07 Jun 2024
ePublished: 24 Jun 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Inj Prev. 2024;13(3): e37317.
doi: 10.34172/jrip.2024.37317
  Abstract View: 673
  PDF Download: 352

Meta-analysis

Examining the impact of aspirin on patients with chronic kidney disease; a systematic review and meta-analysis

Rahime Eskandarian ORCID logo, Samira Mehrabi Pari ORCID logo, Mohammad Memarian* ORCID logo

1 Clinical Research Development Unit, Kowsar Educational, Research and Therapeutic Hospital, Semnan University of Medical Sciences, Semnan, Iran
*Corresponding Author: Mohammad Memarian, Email: dr.mmemarian@semums.ac.ir, Email: draria2014@gmail.com

Abstract

Introduction: Chronic kidney disease (CKD) poses a significant global health burden, and the efficacy and safety of aspirin in CKD patients have yielded conflicting results. Thus, our study aims to investigate the impact of aspirin consumption on individuals with CKD.

Materials and Methods: This comprehensive systematic review and meta-analysis involved searching PubMed, ProQuest, Web of Science, Cochrane, and Google Scholar databases without any time restrictions until December 22, 2023. Data analysis was conducted using STATA 14 software, with a significance level set at P<0.05.

Results: Our analysis encompassed 12 studies involving a total of 92,271 participants. The findings revealed no meaningfully significant relationship between aspirin administration (≤200 mg) and renal failure in these patients (OR: 0.99, 95% CI: 0.86, 1.14). Similarly, the use of low-dose aspirin (≤100 mg) did not impact renal failure in CKD patients (OR: 0.97, 95% CI: 0.81, 1.15). The association between aspirin administration and renal failure in CKD patients aged 50-59 years (OR: 1.11, 95% CI: 0.91, 1.34) and 60-69 years (OR: 0.96, 95% CI: 0.80, 1.15) was not statistically significant. However, aspirin use in CKD patients aged 70-79 demonstrated a reduction in renal failure (OR: 0.34, 95% CI: 0.14, 0.82). Furthermore, there was no statistically significant association between aspirin administration and all-cause death in CKD patients (OR: 0.96, 95% CI: 0.81, 1.13).

Conclusion: Our findings suggest that aspirin consumption does not pose a risk for renal failure or all-cause mortality in CKD individuals.

Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024497581) and Research Registry (UIN: reviewregistry1768) website.


Implication for health policy/practice/research/medical education:

Our meta-analysis showed that aspirin consumption does not pose a risk for renal failure or all-cause mortality in CKD patients.

Please cite this paper as: Eskandarian R, Mehrabi Pari S, Memarian M. Examining the impact of aspirin on patients with chronic kidney disease; a systematic review and meta-analysis. J Renal Inj Prev. 2024; 13(3): e37317. doi: 10.34172/jrip.2024.37317.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 674

Your browser does not support the canvas element.


PDF Download: 352

Your browser does not support the canvas element.